Home » Stocks » PTLA

Portola Pharmaceuticals, Inc. (PTLA)

Jul 1, 2020 - PTLA was delisted (reason: acquired by ALXN)
Stock Price: $18.03 USD 0.00 (0.00%)
Updated Jul 2, 2020 4:00 PM EDT
Market Cap 1.41B
Revenue (ttm) 120.86M
Net Income (ttm) -281.28M
Shares Out 78.48M
EPS (ttm) -3.78
PE Ratio n/a
Forward PE n/a
Dividend n/a
Dividend Yield n/a
Trading Day Jul 2, 2020
Last Price $18.03
Previous Close $18.03
Change ($) 0.00
Change (%) 0.00%
Day's Open -
Day's Range 17.99 - 18.07
Day's Volume 0
52-Week Range 5.31 - 31.73

News

Hide News
PRNewsWire - 8 months ago

SOUTH SAN FRANCISCO, Calif., May 18, 2020 /PRNewswire/ -- Portola Pharmaceuticals, Inc.® (NASDAQ: PTLA) today announced that, due to the public health impact of the coronavirus (COVID-19) pand...

Seeking Alpha - 8 months ago

Portola Pharmaceuticals - This Name You Haven't Heard Of Is The Next Big COVID-19 Company

PRNewsWire - 8 months ago

SOUTH SAN FRANCISCO, Calif., May 14, 2020 /PRNewswire/ -- Portola Pharmaceuticals, Inc.® (Nasdaq: PTLA) announced that the U.S. Centers for Medicare & Medicaid Services (CMS) has proposed exte...

Zacks Investment Research - 8 months ago

Portola Pharmaceuticals (PTLA) delivered earnings and revenue surprises of -18.92% and -26.45%, respectively, for the quarter ended March 2020. Do the numbers hold clues to what lies ahead for...

The Motley Fool - 8 months ago

Alexion Pharmaceuticals made a move to acquire Portola Pharmaceuticals.

24/7 Wall Street - 8 months ago

Portola Pharmaceuticals Inc. (NASDAQ: PTLA) shares more than doubled on Tuesday after the company announced that it would be acquired by Alexion Pharmaceuticals Inc.

Investors Business Daily - 8 months ago

Alexion Pharmaceuticals pledged to buy Portola Pharmaceuticals on Tuesday in a deal that combines two blood disease-focused biotech companies. Alexion stock slipped, but Portola stock flew.

Other stocks mentioned: ALXN
Seeking Alpha - 10 months ago

Portola Pharmaceuticals, Inc. (PTLA) CEO Scott Garland on Q4 2019 Results - Earnings Call Transcript

Zacks Investment Research - 11 months ago

Investors need to pay close attention to Portola Pharmaceuticals (PTLA) stock based on the movements in the options market lately.

Seeking Alpha - 1 year ago

Portola: Still Bleeding, What I'm Looking For Before Buying It Back

The Motley Fool - 1 year ago

Investors ran away after the business provided preliminary full-year 2019 results.

Market Watch - 1 year ago

Shares of Portola Pharmaceuticals Inc. PTLA, -43.25% tumbled 45% in trading on Friday after the company shared "disappointing" preliminary fourth-quarter revenue for Andexxa, its antidote for ...

CNBC - 1 year ago

Take a look at the companies making headlines after the bell.

Other stocks mentioned: ISRG, KBH, NLOK, MRNA
The Motley Fool - 1 year ago

These three small companies have the potential to make you a lot of money.

Other stocks mentioned: CARA, NSTG
The Motley Fool - 1 year ago

If you want to see your investment in the biotech market grow two-fold, these are the top stocks to buy.

Other stocks mentioned: AMRN, TNDM
The Motley Fool - 1 year ago

These three healthcare companies have a lot of good signs going for them.

Other stocks mentioned: AZN, NVS
Seeking Alpha - 1 year ago

Portola Pharmaceuticals' (PTLA) CEO Scott Garland on Q3 2019 Results - Earnings Call Transcript

Zacks Investment Research - 1 year ago

Portola Pharmaceuticals (PTLA) delivered earnings and revenue surprises of 35.37% and 6.78%, respectively, for the quarter ended September 2019. Do the numbers hold clues to what lies ahead fo...

Zacks Investment Research - 1 year ago

Portola Pharmaceuticals (PTLA) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Seeking Alpha - 1 year ago

Portola has sidelined Bevyxxa after failing to secure its approval in Europe and focused its attention on Factor Xa reversal agent Andexxa.

The Motley Fool - 1 year ago

What should investors think of this biotech stock and its signature drug candidate Andexxa?

The Motley Fool - 1 year ago

The company's second-quarter revenue is sparking optimism for future growth.

Seeking Alpha - 1 year ago

Portola Pharmaceuticals, Inc. (PTLA) CEO Scott Garland on Q2 2019 Results - Earnings Call Transcript

Zacks Investment Research - 1 year ago

Portola Pharmaceuticals (PTLA) delivered earnings and revenue surprises of 12.38% and 17.04%, respectively, for the quarter ended June 2019. Do the numbers hold clues to what lies ahead for th...

Zacks Investment Research - 1 year ago

Portola Pharmaceuticals (PTLA) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Seeking Alpha - 1 year ago

Portola Pharmaceuticals' products present clinicians with many headaches, and the company's equity has been beaten down recently.

The Motley Fool - 1 year ago

The company's still struggling to transition from clinical stage to commercial stage, but it's making progress.

Seeking Alpha - 1 year ago

Portola Pharmaceuticals' (PTLA) CEO Scott Garland on Q1 2019 Results - Earnings Call Transcript

The Motley Fool - 1 year ago

First-quarter financial results are failing to spark investor optimism on concerns over cash burn.

Zacks Investment Research - 1 year ago

Portola Pharmaceuticals (PTLA) delivered earnings and revenue surprises of 0.00% and 6.38%, respectively, for the quarter ended March 2019. Do the numbers hold clues to what lies ahead for the...

The Motley Fool - 1 year ago

This commercial-stage company's success depends heavily on the demand for one drug.

Seeking Alpha - 1 year ago

Portola Pharmaceuticals is a growth company that is undergoing strong fundamentals development.

About PTLA

Portola Pharmaceuticals, a biopharmaceutical company, develops and commercializes novel therapeutics in the areas of thrombosis, and other hematologic disorders and inflammation in Europe and the United States. Its lead product Andexxa, an antidote for the treatment of rivaroxaban and apixaban under the Ondexxya Brand. The company offers Bevyxxa (betrixaban), an oral, once-daily Factor Xa inhibitor for the prevention of venous thromboembolism in adult patients for an acute medical illness. It also develops cerdulatinib, an investigational oral,... [Read more...]

Industry
Biotechnology
IPO Date
May 22, 2013
CEO
J. Scott Garland
Employees
408
Stock Exchange
NASDAQ
Ticker Symbol
PTLA
Full Company Profile

Financial Performance

In 2019, PTLA's revenue was $116.64 million, an increase of 190.66% compared to the previous year's $40.13 million. Losses were -$290.66 million, -17.01% less than in 2018.

Financial Statements